Beware of scams: Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

You can also contact A*STAR via our online form or call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

Antibodies (resized)

Realise Quality Processes for Biomanufacturing

To align with EDB’s drive to expand the footprint of Singapore as a biopharma hub
Cells (resized)

Research Excellence

A centre of excellence for groundbreaking research in Proteins, Cells, and Nucleic Acids bioprocessing technologies
Partnership (resized)

Industry Collaboration

Cultivating partnerships with industry to advance innovations and translate research into industrial applications
Bioreactor (resized)

Talent Development

Providing development and training programmes to support biomanufacturing and research activities in Singapore

A*STAR Bioprocessing Technology Institute (BTI)

Who We Are

A*STAR Bioprocessing Technology Institute (BTI) focuses on advancing bioprocessing technologies and research over its 35-year history. Our current vision is to Realise Quality Processes for Biomanufacturing, with a strong emphasis on Proteins, Cells, and Nucleic Acids.

 

BTI’s Key Focus Areas

To achieve BTI’s vision of ensuring Quality Processes for Biomanufacturing, the institute develops innovative research capabilities and advanced biomanufacturing technologies. Modality-specific strategies are key to BTI achieving its mission of developing Singapore's biomanufacturing sector where asset classes are in various stages of maturity and development.

Read More

BTI Focus Area (PCN)

 

BTI's Core Capabilities

BTI’s core capabilities are systematically organised around its four principal divisions, which oversee 19 Enabling Research Groups, and Technology Platforms and Consortia. The matrix structure of BTI’s divisions enables the swift and flexible assembly of research teams with synergistic capabilities, allowing them to effectively address research and industry problem statements.

Read More

BTI Capabilities

 

Rapid Screening of Cancer-Targeting Receptors in Natural Killer (NK) Cells

22 Jan 2026

Autologous chimeric antigen receptor (CAR)-T cell therapy involves the derivation of T cells from a patient, their genetic modification outside of the body with CAR specifically targeting cancer cells and subsequent reinfusion of CAR-T cells into the patient. Despite its remarkable success in treating liquid cancers, CAR-T therapy can result in adverse effects to the patient. Alternative immune cell types such as natural killer (NK) cells can be derived from healthy human donors, engineered to express CAR and administered to many patients in much safer manner that produces little to no side effects. However, modifying NK cells to express CAR is challenging due to the long process time required for and poor efficiency of virus-based CAR delivery. In this study, we developed an optimized non-viral protocol to deliver CAR mRNA payload into NK cells for rapid screening to identify CAR candidates that improve cancer killing by NK cells.

Read more: https://www.a-star.edu.sg/bti/bti-research-highlights/rapid-screening-of-cancer-targeting-receptors-in-natural-killer-(nk)-cells

Posted in: BTI Research Highlights
Related Topics -

A*STAR celebrates International Women's Day

A*STAR Women In Science

From groundbreaking discoveries to cutting-edge research, our researchers are empowering the next generation of female science, technology, engineering and mathematics (STEM) leaders.

Get inspired by our #WomeninSTEM